C
Curtis D. Collins
Researcher at Mercy Health
Publications - 42
Citations - 1127
Curtis D. Collins is an academic researcher from Mercy Health. The author has contributed to research in topics: Antimicrobial stewardship & Pharmacy. The author has an hindex of 14, co-authored 42 publications receiving 998 citations. Previous affiliations of Curtis D. Collins include University of Michigan & Mercy Medical Center (Baltimore, Maryland).
Papers
More filters
Journal ArticleDOI
Impact of Rapid Organism Identification via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Combined With Antimicrobial Stewardship Team Intervention in Adult Patients With Bacteremia and Candidemia
Angela M. Huang,Duane W. Newton,Anjly Kunapuli,Tejal N Gandhi,Laraine Washer,Jacqueline Isip,Curtis D. Collins,Jerod Nagel +7 more
TL;DR: MALDI-TOF with AST intervention decreased time to organism identification and time to effective and optimal antibiotic therapy and acceptance of an AST intervention was associated with a trend toward reduced mortality on multivariable analysis.
Journal ArticleDOI
Impact of an Antimicrobial Stewardship Program Comprehensive Care Bundle on Management of Candidemia
Allen Antworth,Curtis D. Collins,Anjly Kunapuli,Kristin C. Klein,Peggy L. Carver,Tejal K. Gandhi,Laraine Washer,Jerod Nagel +7 more
TL;DR: To analyze the impact of a comprehensive care bundle directed by an antimicrobial stewardship team (AST) on the management of candidemia, a large number of patients with candidemia are referred to an AST for treatment.
Journal ArticleDOI
Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
TL;DR: Results of the model showed that fidaxomicin may be a more cost-effective option for the treatment of CDIs when compared with oral vancomycin under most scenarios tested.
Journal ArticleDOI
Managing antimicrobial resistance in intensive care units.
TL;DR: Antimicrobial stewardship programs provide an organized way to implement these strategies and can enhance the intensive care unit physician's success in improving patient outcomes and combating antimicrobial resistance in theintensive care unit.
Journal ArticleDOI
Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
TL;DR: The decision model indicated that use of posaconazole as prophylaxis in patients with prolonged neutropenia should result in lower overall treatment costs relative to the cost of fluconazole or itraconazoles.